T-DM1 as a New Treatment Option for Patients with Metastatic HER2-positive Breast Cancer in Clinical Practice. [electronic resource]
Producer: 20160428Description: 5085-90 p. digitalISSN:- 1791-7530
- Ado-Trastuzumab Emtansine
- Adult
- Aged
- Antibodies, Monoclonal, Humanized -- adverse effects
- Antineoplastic Agents -- adverse effects
- Breast Neoplasms -- drug therapy
- Cohort Studies
- Disease Progression
- Female
- Humans
- Kaplan-Meier Estimate
- Maytansine -- adverse effects
- Middle Aged
- Neoplasm Metastasis
- Practice Patterns, Physicians'
- Receptor, ErbB-2 -- metabolism
- Trastuzumab
- Treatment Outcome
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.